Patents by Inventor Tigran Aivazian

Tigran Aivazian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTLA Fusion Protein Agonists and Uses Thereof
    Publication number: 20240247047
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: February 15, 2024
    Publication date: July 25, 2024
    Applicants: Sanford Burnham Prebys Medical Discovery Institute, PFIZER INC.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Hypoimmunogenic Biotherapeutics
    Publication number: 20240238422
    Abstract: The present disclosure provides hypoimmunogenic biotherapeutic compositions that suppress the development of an immune response to themselves in an individual. The present disclosure also provides pharmaceutical compositions that include such hypoimmunogenic biotherapeutics, methods for making such hypoimmunogenic biotherapeutics, and methods for using such hypoimmunogenic biotherapeutics as therapeutics and in research.
    Type: Application
    Filed: January 10, 2022
    Publication date: July 18, 2024
    Inventors: Richard James Glynne, Tigran Aivazian
  • Autoantigens Engineered to Suppress Autoimmune Response
    Publication number: 20240216490
    Abstract: The present disclosure provides engineered antigen compositions that reduce immune response to the antigen in a subject having an immune response to the antigen. The present disclosure also provides pharmaceutical compositions that include such engineered autoantigens and methods for making such engineered autoantigens. Methods for using such engineered antigens as therapeutics and in research are also disclosed.
    Type: Application
    Filed: July 12, 2023
    Publication date: July 4, 2024
    Inventors: Richard James Glynne, Tigran Aivazian, James Paulson
  • BTLA fusion protein agonists and uses thereof
    Patent number: 11939367
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: March 26, 2024
    Assignees: Sanford Burnham Prebys Medical Discovery Institute, Pfizer Inc.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
    Publication number: 20220025017
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: March 1, 2021
    Publication date: January 27, 2022
    Inventors: Carl F. WARE, John SEDY, Tigran AIVAZIAN, Brian MILLER, Natasha K. CRELLIN
  • BTLA fusion protein agonists and uses thereof
    Patent number: 10961297
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 30, 2021
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, PFIZER INC.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
    Publication number: 20180170999
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: June 29, 2016
    Publication date: June 21, 2018
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Linker peptides and polypeptides comprising same
    Patent number: 9409950
    Abstract: The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: August 9, 2016
    Assignee: Biogen MA Inc.
    Inventors: Brian Robert Miller, Scott Glaser, Justin Caravella, Susan Foley, Xiaoping Hronowski, Tigran Aivazian